← Back to home

FDA Approves First DNA-Based Immunotherapy for a Rare Airway Disease

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

The Food and Drug Administration on Friday, Oct. 30, gave accelerated approval to Voceryq, an Inovio Pharmaceuticals…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

2 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home